Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PDEX NASDAQ:RXST NASDAQ:SKYA NASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePDEXPro-Dex$62.20-1.1%$57.59$23.47▼$68.99$200.89M-0.0247,764 shs99,816 shsRXSTRxSight$4.71-1.9%$6.22$4.48▼$14.88$198.70M1.14847,276 shs1.01 million shsSKYASkyAI, Inc. Common Stock$1.12-0.9%$1.67$1.02▼$18.23$47.82M2.04263,475 shs165,947 shsSMTISanara MedTech$20.81-3.2%$20.27$16.05▼$35.95$197.02M1.2141,503 shs48,928 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePDEXPro-Dex+1.52%-6.09%+11.36%+29.84%+50.67%RXSTRxSight+4.35%-5.88%-13.04%-34.52%-67.81%SKYASkyAI, Inc. Common Stock+1.80%-9.60%-43.50%-40.53%-81.26%SMTISanara MedTech-6.48%-2.80%+5.19%+10.37%-25.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePDEXPro-Dex$62.20-1.1%$57.59$23.47▼$68.99$200.89M-0.0247,764 shs99,816 shsRXSTRxSight$4.71-1.9%$6.22$4.48▼$14.88$198.70M1.14847,276 shs1.01 million shsSKYASkyAI, Inc. Common Stock$1.12-0.9%$1.67$1.02▼$18.23$47.82M2.04263,475 shs165,947 shsSMTISanara MedTech$20.81-3.2%$20.27$16.05▼$35.95$197.02M1.2141,503 shs48,928 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePDEXPro-Dex+1.52%-6.09%+11.36%+29.84%+50.67%RXSTRxSight+4.35%-5.88%-13.04%-34.52%-67.81%SKYASkyAI, Inc. Common Stock+1.80%-9.60%-43.50%-40.53%-81.26%SMTISanara MedTech-6.48%-2.80%+5.19%+10.37%-25.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePDEXPro-Dex 2.33Hold$70.0012.69% UpsideRXSTRxSight 1.93Reduce$9.44100.31% UpsideSKYASkyAI, Inc. Common Stock 1.00SellN/AN/ASMTISanara MedTech 2.25Hold$34.0063.42% UpsideCurrent Analyst Ratings BreakdownLatest SKYA, PDEX, RXST, and SMTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026SMTISanara MedTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/22/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/12/2026SMTISanara MedTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026RXSTRxSight Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $9.005/7/2026RXSTRxSight Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.005/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026SKYASkyAI, Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SMTISanara MedTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPDEXPro-Dex$66.59M2.98$3.14 per share19.76$11.23 per share5.53RXSTRxSight$127.48M1.53N/AN/A$6.70 per share0.70SKYASkyAI, Inc. Common Stock$396.90K119.43N/AN/A$9.12 per share0.12SMTISanara MedTech$103.12M1.85$0.54 per share38.67$0.67 per share31.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePDEXPro-Dex$8.98M$3.6217.2922.34N/A16.08%22.78%14.30%7/8/2026 (Estimated)RXSTRxSight-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/6/2026 (Estimated)SKYASkyAI, Inc. Common Stock-$282.50M-$1.63N/AN/AN/AN/A-157.91%-154.40%N/ASMTISanara MedTech-$37.56M-$3.77N/AN/AN/A-31.23%-3.19%-0.56%8/12/2026 (Estimated)Latest SKYA, PDEX, RXST, and SMTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SKYASkyAI, Inc. Common StockN/A-$1.19N/A-$1.19N/A$0.19 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/24/2026Q4 2025SMTISanara MedTech$0.11$0.04-$0.07-$0.19$27.90 million$27.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPDEXPro-DexN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASKYASkyAI, Inc. Common StockN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPDEXPro-Dex0.323.672.14RXSTRxSightN/A10.208.93SKYASkyAI, Inc. Common StockN/A8.288.08SMTISanara MedTech6.592.282.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPDEXPro-Dex15.28%RXSTRxSight78.78%SKYASkyAI, Inc. Common Stock17.17%SMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipPDEXPro-Dex45.90%RXSTRxSight10.05%SKYASkyAI, Inc. Common Stock20.00%SMTISanara MedTech42.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePDEXPro-Dex1403.19 million1.73 millionNot OptionableRXSTRxSight22041.40 million37.24 millionOptionableSKYASkyAI, Inc. Common Stock5542.32 million33.86 millionNot OptionableSMTISanara MedTech609.16 million5.32 millionNot OptionableSKYA, PDEX, RXST, and SMTI HeadlinesRecent News About These CompaniesSanara MedTech Earnings Call Signals Profitable Growth2 hours ago | theglobeandmail.comSanara MedTech (NASDAQ:SMTI) Stock Price Down 1.6% - Should You Sell?June 9 at 1:43 AM | americanbankingnews.comFinancial Analysis: Haleon (NYSE:HLN) and Sanara MedTech (NASDAQ:SMTI)June 4, 2026 | americanbankingnews.comSanara MedTech (SMTI) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comHow The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays PutMay 23, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 19, 2026 | globenewswire.comSanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 14, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 14, 2026 | prnewswire.comSanara MedTech: From Cash Burner To Profitable GrowthMay 14, 2026 | seekingalpha.comSanara MedTech Inc (SMTI) Q1 2026 Earnings Report Preview: What To ExpectMay 13, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 12, 2026 | globenewswire.comSanara MedTech Inc. (SMTI) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)May 11, 2026 | globenewswire.comSMTI Investors Have Opportunity to Join Sanara MedTech Inc. Fraud Investigation with the Schall Law FirmMay 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 7, 2026 | prnewswire.comHow Sanara MedTech (SMTI) Is Reframing Its Growth Story Around A Steady US$34 TargetMay 5, 2026 | finance.yahoo.comSanara MedTech (SMTI) Q4 2025 Earnings TranscriptMay 4, 2026 | fool.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIApril 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYA, PDEX, RXST, and SMTI Company DescriptionsPro-Dex NASDAQ:PDEX$62.20 -0.72 (-1.14%) Closing price 04:00 PM EasternExtended Trading$62.80 +0.60 (+0.96%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.RxSight NASDAQ:RXST$4.71 -0.09 (-1.88%) Closing price 04:00 PM EasternExtended Trading$4.80 +0.09 (+1.85%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SkyAI, Inc. Common Stock NASDAQ:SKYA$1.12 -0.01 (-0.88%) As of 04:00 PM EasternSkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.Sanara MedTech NASDAQ:SMTI$20.81 -0.69 (-3.21%) Closing price 04:00 PM EasternExtended Trading$21.52 +0.72 (+3.44%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
